肝硬化门静脉高压症多学科诊治(基于肝静脉压力梯度)专家共识

北京医师协会门静脉高压专科医师分会; 中国研究型医院学会肝病专业委员会门静脉高压学组; 中国研究型医院学会肝病专业委员会

doi:10.3969/j.issn.1001-5256.2021.09.008

肝硬化门静脉高压症多学科诊治(基于肝静脉压力梯度)专家共识

DOI: 10.3969/j.issn.1001-5256.2021.09.008

丁惠国(首都医科大学附属北京佑安医院肝病消化中心)、杨永平(解放军总医院第五中心肝病部)、贾继东(首都医科大学附属北京友谊医院肝病研究中心)、徐小元(北京大学第一医院感染科)、滕皋军(东南大学附属中大医院介入治疗中心)

指导专家： (按姓氏笔画排序)

讨论专家： (按姓氏笔画排序)

执笔：吕少诚(首都医科大学附属北京朝阳医院肝胆外科)、高沿航(吉林大学第一医院肝病科)、王磊(首都医科大学附属北京世纪坛医院介入中心)、张珂(首都医科大学附属北京地坛医院肝胆外科)

马红(首都医科大学附属北京友谊医院肝病研究中心)、王中峰(吉林大学第一医院肝病科)、王宇(首都医科大学附属北京友谊医院肝病研究中心)、王孟龙(首都医科大学附属北京佑安医院肝胆外科)、王笑梅(首都医科大学附属北京地坛医院肝病中心)、王健(北京大学第一医院介入血管外科)、王涛(烟台毓璜顶医院介入治疗科)、王睿林(解放军总医院第五医学中心肝病内科)、尤红(首都医科大学附属北京友谊医院肝病研究中心)、计嘉军(首都医科大学附属北京同仁医院肝胆外科)、邢卉春(首都医科大学附属北京地坛医院肝病中心)、朱震宇(解放军总医院第五医学中心肝胆外科)、刘正新(首都医科大学附属北京朝阳医院消化内科)、齐瑞兆(解放军总医院第五医学中心肝胆外科)、祁兴顺(北部战区总医院消化内科)、孙刚(解放军总医院消化内科)、孙颖(解放军总医院第五医学中心肝病内科)、纪冬(解放军总医院第五医学中心肝病内科)、苏海滨(解放军总医院第五医学中心肝衰中心)、杜时雨(中日友好医院消化科)、李坪(首都医科大学附属北京地坛医院消化内科)、李志伟(深圳三院肝胆外科)、李婷婷(首都医科大学附属北京世纪坛医院介入中心)、杨长青(同济大学附属同济医院内科)、杨松(首都医科大学附属北京地坛医院肝病中心)、何福亮(首都医科大学附属北京友谊医院肝病研究中心)、邹正升(解放军总医院第五医学中心肝病部)、宋蕊(首都医科大学附属北京地坛医院感染科)、张月宁(首都医科大学附属北京佑安医院肝病消化中心)、张跃伟(清华长庚医院介入治疗科)、张敏(解放军总医院第五医学中心肝病内科)、张晶(首都医科大学附属北京佑安医院肝病中心)、陈国凤(解放军总医院第五医学中心肝硬化中心)、陈雷(北京大学人民医院肝胆外科)、陈靖(福建医科大学附属第一医院肝病中心)、范振平(解放军总医院第五医学中心老年肝病诊疗中心)、范振华(首都医科大学附属北京世纪坛医院介入中心)、欧晓娟(首都医科大学附属北京友谊医院肝病中心)、易永祥(南京市第二医院肝病中心)、帖军(空军军医大学第一附属医院消化科)、岳振东(首都医科大学附属北京世纪坛医院介入中心)、金波(解放军总医院第五医学中心肝病科)、周强(吉林大学第一医院肝病科)、孟明明(首都医科大学附属北京世纪坛医院消化科)、孟繁平(解放军总医院第五医学中心肝病内科)、赵鸿(北京大学第一医院感染疾病科)、赵洪伟(首都医科大学附属北京同仁医院介入治疗科)、胡瑾华(解放军总医院第五医学中心肝衰竭中心)、闾军(首都医科大学附属北京佑安医院肿瘤内科)、洪智贤(解放军总医院第五医学中心肝胆外科)、宫嫚(解放军总医院第五医学中心肝病内科)、聂为民(解放军总医院第五医学中心感染性疾病诊疗与研究中心)、栗光明(首都医科大学附属北京佑安医院肝胆外科)、贾哲(首都医科大学附属北京地坛医院肝胆外科)、贾淑娟(北京大学首钢医院消化内科)、高飞(中山大学肿瘤防治中心影像与微创介入中心)、郭江(首都医科大学附属北京地坛医院介入治疗科)、蒋力(首都医科大学附属北京地坛医院肝胆外科)、韩莹(首都医科大学附属北京佑安医院肝病免疫科)、游绍莉(解放军总医院第五医学中心肝衰中心)、谢雯(首都医科大学附属北京地坛医院肝病中心)

利益冲突声明：所有作者均声明不存在利益冲突

详细信息

通信作者： 刘福全(首都医科大学附属北京世纪坛医院介入中心)，lfuquan@aliyun.com；牛俊奇(吉林大学第一医院肝病科)，junqiniu@aliyun.com；郎韧(首都医科大学附属北京朝阳医院肝胆外科)，dr_langren@126.com

中图分类号: R575.2
计量
- 文章访问数: 2087
- HTML全文浏览量: 219
- PDF下载量: 518
- 被引次数: 0
出版历程
- 收稿日期: 2021-07-14
- 录用日期: 2021-07-14
- 出版日期: 2021-09-20

Expert consensus on multidisciplinary diagnosis and treatment of cirrhotic portal hypertension (based on hepatic venous pressure gradient)

摘要

- 肝硬化 /
- 高血压，门静脉 /
- 肝静脉压力梯度 /
- 共识
- Liver Cirrhosis /
- Hypertension, Portal /
- Hepatic Venous Pressure Gradient /
- Consensus

HTML全文

图 1 肝硬化门静脉高压症病理生理过程

注：TIPS，经颈静脉肝内门体静脉分流术；NSBBs，非选择性β受体阻滞剂；SMT, 生长抑素；VP, 血管加压素。

下载: 全尺寸图片幻灯片

图 2 HVPG与肝硬化门静脉高压症不同分期之间的关系

下载: 全尺寸图片幻灯片

图 3 代偿期肝硬化门静脉高压症患者的治疗流程

下载: 全尺寸图片幻灯片

图 4 失代偿期肝硬化门静脉高压症患者的治疗流程

下载: 全尺寸图片幻灯片

参考文献(60)

[1]	WANG X, LIN SX, TAO J, et al. Study of liver cirrhosis over ten consecutive years in Southern China[J]. World J Gastroenterol, 2014, 20(37): 13546-13555. DOI: 10.3748/wjg.v20.i37.13546.
[2]	XIE WF, HU PF. Diagnosis and treatment of cirrhotic portal hypertension: A review over the last 100 years[J]. Chin J Dig, 2015, 35(1): 9-11. DOI: 10.3760/cma.j.issn.0254-1432.2015.01.005. 谢渭芬, 胡平方. 肝硬化门静脉高压症诊治百年回顾[J]. 中华消化杂志, 2015, 35(1): 9-11. DOI: 10.3760/cma.j.issn.0254-1432.2015.01.005.
[3]	TRIPATHI D, STANLEY AJ, HAYES PC, et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients[J]. Gut, 2015, 64(11): 1680-1704. DOI: 10.1136/gutjnl-2015-309262.
[4]	Chinese Society of Spleen and Portal Hypertension Surgery, Chinese Society of Surgery, Chinese Medical Association. Expert consensus on diagnosis and treatment of esophagogastric variceal bleeding in cirrhotic portal hypertension(2019 edition)[J]. Chin J Dig Surg, 2019, 18(12): 1087-1093. DOI: 10.3760/cma.j.issn.1673-9752.2019.12.001. 中华医学会外科学分会脾及门静脉高压外科学组. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2019版)[J]. 中华消化外科杂志, 2019, 18(12): 1087-1093. DOI: 10.3760/cma.j.issn.1673-9752.2019.12.001.
[5]	Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006. 中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
[6]	GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65(1): 310-335. DOI: 10.1002/hep.28906.
[7]	ABRALDES JG, SARLIEVE P, TANDON P. Measurement of portal pressure[J]. Clin Liver Dis, 2014, 18(4): 779-792. DOI: 10.1016/j.cld.2014.07.002.
[8]	Chinese Portal Hypertension Diagnosis and Monitoring Study Group (CHESS), Minimally Invasive Intervention Collaborative Group, Chinese Society of Gastroenterology, Emergency Intervention Committee, Chinese College of Interventionalists, et al. Consensus on clinical application of hepatic venous pressure gradient in China (2018)[J]. J Clin Hepatol, 2018, 34(12): 2526-2536. DOI: 10.3969/j.issn.1001-5256.2018.12.008. 中国门静脉高压诊断与监测研究组(CHESS), 中华医学会消化病学分会微创介入协作组, 中国医师协会介入医师分会急诊介入专业委员会, 等. 中国肝静脉压力梯度临床应用专家共识(2018版)[J]. 临床肝胆病杂志, 2018, 34(12): 2526-2536. DOI: 10.3969/j.issn.1001-5256.2018.12.008.
[9]	de FRANCHIS R. Evolving consensus in portal hypertension. Report of the Baveno Ⅳ consensus workshop on methodology of diagnosis and therapy in portal hypertension[J]. J Hepatol, 2005, 43(1): 167-176. DOI: 10.1016/j.jhep.2005.05.009.
[10]	RIPOLL C, GROSZMANN R, GARCIA-TSAO G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis[J]. Gastroenterology, 2007, 133(2): 481-488. DOI: 10.1053/j.gastro.2007.05.024.
[11]	JINDAL A, BHARDWAJ A, KUMAR G, et al. Clinical decompensation and outcomes in patients with compensated cirrhosis and a hepatic venous pressure gradient ≥20 mm Hg[J]. Am J Gastroenterol, 2020, 115(10): 1624-1633. DOI: 10.14309/ajg.0000000000000653.
[12]	Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Gastroenterology, Chinese Medical Association, Chinese Society of Endoscopy, Chinese Medical Association. Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002. 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002.
[13]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of ascites and complications in cirrhosis[J]. J Clin Hepatol, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003. 中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003.
[14]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of hepatic encephalopathy in cirrhosis[J]. J Clin Hepatol, 2018, 34(10): 2076-2089. DOI: 10.3969/j.issn.1001-5256.2018.10.007. 中华医学会肝病学分会. 肝硬化肝性脑病诊疗指南[J]. 临床肝胆病杂志, 2018, 34(10): 2076-2089. DOI: 10.3969/j.issn.1001-5256.2018.10.007.
[15]	TOSHIKUNI N, TAKUMA Y, TSUTSUMI M. Management of gastroesophageal varices in cirrhotic patients: Current status and future directions[J]. Ann Hepatol, 2016, 15(3): 314-325. DOI: 10.5604/16652681.1198800.
[16]	QI XL. Standardize hepatic venous pressure gradient measurement and optimize clinical practice of portal hypertension[J]. Chin J Radiol, 2018, 52(11): 809-810. DOI: 10.3760/cma.j.issn.1005-1201.2018.11.001. 祁小龙. 规范肝静脉压力梯度检测, 优化门静脉高压诊疗实践[J]. 中华放射学杂志, 2018, 52(11): 809-810. DOI: 10.3760/cma.j.issn.1005-1201.2018.11.001.
[17]	de FRANCHIS R, Baveno Ⅵ Faculty. Expanding consensus in portal hypertension: Report of the Baveno Ⅵ Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022.
[18]	WANG HL, SUN JH. Role of hepatic venous pressure gradient in the overall management process of portal hypertension[J]. Chin J Hepatol, 2020, 28(9): 728-731. DOI: 10.3760/cma.j.cn501113-20200613-00313. 王宏亮, 孙军辉. 肝静脉压力梯度在门静脉高压全病程管理中的作用[J]. 中华肝脏病杂志, 2020, 28(9): 728-731. DOI: 10.3760/cma.j.cn501113-20200613-00313.
[19]	REIBERGER T, PVSPÖK A, SCHODER M, et al. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth Ⅲ)[J]. Wien Klin Wochenschr, 2017, 129(Suppl 3): 135-158. DOI: 10.1007/s00508-017-1262-3.
[20]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[21]	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for hepatitis C (2019 version)[J]. J Clin Hepatol, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008. 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.
[22]	HERNÁNDEZ-GEA V, ARACIL C, COLOMO A, et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers[J]. Am J Gastroenterol, 2012, 107(3): 418-427. DOI: 10.1038/ajg.2011.456.
[23]	SCHWARZER R, KIVARANOVIC D, PATERNOSTRO R, et al. Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: A dose-response study[J]. Aliment Pharmacol Ther, 2018, 47(8): 1162-1169. DOI: 10.1111/apt.14576.
[24]	VLACHOGIANNAKOS J, KOUGIOUMTZIAN A, TRIANTOS C, et al. Clinical trial: The effect of somatostatin vs. octreotide in preventing post-endoscopic increase in hepatic venous pressure gradient in cirrhotics with bleeding varices[J]. Aliment Pharmacol Ther, 2007, 26(11-12): 1479-1487. DOI: 10.1111/j.1365-2036.2007.03539.x.
[25]	BAIK SK, JEONG PH, JI SW, et al. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: A randomized comparison[J]. Am J Gastroenterol, 2005, 100(3): 631-635. DOI: 10.1111/j.1572-0241.2005.41381.x.
[26]	YACHIMSKI PS, FARRELL EA, HUNT DP, et al. Proton pump inhibitors for prophylaxis of nosocomial upper gastrointestinal tract bleeding: Effect of standardized guidelines on prescribing practice[J]. Arch Intern Med, 2010, 170(9): 779-783. DOI: 10.1001/archinternmed.2010.51.
[27]	MORATALLA A, AMPUERO J, BELLOT P, et al. Lactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy[J]. Liver Int, 2017, 37(2): 212-223. DOI: 10.1111/liv.13200.
[28]	CHEN J, LIU JT, MENG K, et al. Relationship between endoscopic features of cirrhosis with gastroesophageal varices and hepatic venous pressure gradient[J]. Chin J Gastroenterol Hepatol, 2017, 26(11): 1252-1254. DOI: 10.3969/j.issn.1006-5709.2017.11.014. 陈俊, 刘江涛, 孟科, 等. 肝硬化食管胃静脉曲张内镜特征与肝静脉压力梯度相关性研究[J]. 胃肠病学和肝病学杂志, 2017, 26(11): 1252-1254. DOI: 10.3969/j.issn.1006-5709.2017.11.014.
[29]	SHI YC, MA X, GUO ZY, et al. Reasons and risk factors for irregular-interval endoscopic variceal sclerotherapy in patients with esophageal variceal bleeding[J]. J Dig Dis, 2016, 17(11): 764-772. DOI: 10.1111/1751-2980.12419.
[30]	XIAO Y, YU HG, CHEN MK. Endoscopic management strategies ofr variceal bleeding in cirrhosis[J]. Chin J Dig Endosc, 2018, 35(2): 84-88. DOI: 10.3760/cma.j.issn.1007-5232.2018.02.002. 肖勇, 于红刚, 陈明锴. 肝硬化门静脉高压食管胃静脉曲张出血的内镜诊治策略[J]. 中华消化内镜杂志, 2018, 35(2): 84-88. DOI: 10.3760/cma.j.issn.1007-5232.2018.02.002.
[31]	HE ZD, SUN G, JIANG H, et al. Treatment of gastroesophageal varices of Le, g type with endoscopic tissue adhesive injection combined with sequential endoscopic variceal ligation[J]. Chin J Dig Endosc, 2015, 32(12): 800-803. DOI: 10.3760/cma.j.issn.1007-5232.2015.12.005. 何占娣, 孙刚, 江华, 等. 内镜组织胶注射序贯套扎治疗Le, g型食管胃静脉曲张[J]. 中华消化内镜杂志, 2015, 32(12): 800-803. DOI: 10.3760/cma.j.issn.1007-5232.2015.12.005.
[32]	SHEIBANI S, KHEMICHIAN S, KIM JJ, et al. Randomized trial of 1-week versus 2-week intervals for endoscopic ligation in the treatment of patients with esophageal variceal bleeding[J]. Hepatology, 2016, 64(2): 549-555. DOI: 10.1002/hep.28597.
[33]	WAN YP, WANG AJ, ZHU X. Research advances in endoscopic ultrasound-guided treatment of portal hypertension-associated varices[J]. Chin J Dig Endosc, 2018, 35(11): 861-864. DOI: 10.3760/cma.j.issn.1007-5232.2018.11.015. 万义鹏, 汪安江, 朱萱. 超声内镜引导治疗门静脉高压相关性静脉曲张的研究进展[J]. 中华消化内镜杂志, 2018, 35(11): 861-864. DOI: 10.3760/cma.j.issn.1007-5232.2018.11.015.
[34]	ZHAO Y, WANG S, LI C, et al. Synchronous hybrid procedure combining interventional radiology and endoscopy for esophagogastric varices with large gastro-renal shunt[J]. Medicine (Baltimore), 2020, 99(17): e19727. DOI: 10.1097/MD.0000000000019727.
[35]	LU Y, LOFFROY R, LAU JY, et al. Multidisciplinary management strategies for acute non-variceal upper gastrointestinal bleeding[J]. Br J Surg, 2014, 101(1): e34-e50. DOI: 10.1002/bjs.9351.
[36]	HOLSTER IL, KUIPERS EJ, VAN BUUREN HR, et al. Self-expandable metal stents as definitive treatment for esophageal variceal bleeding[J]. Endoscopy, 2013, 45(6): 485-488. DOI: 10.1055/s-0032-1326227.
[37]	ZHAO Y, GUO L, HUANG Q, et al. Observation of immediate and mid-term effects of partial spleen embolization in reducing hepatic venous pressure gradient[J]. Medicine (Baltimore), 2019, 98(47): e17900. DOI: 10.1097/MD.0000000000017900.
[38]	The Chinese College of Interventionalists. CCI clinical practice guidelines: Management of TIPS for portal hypertension (2019 edition)[J]. J Clin Hepatol, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010. 中国医师协会介入医师分会. 中国门静脉高压经颈静脉肝内门体分流术临床实践指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010
[39]	HERNÁNDEZ-GEA V, PROCOPET B, GIRÁLDEZ Á, et al. Preemptive-TIPS improves outcome in high-risk variceal bleeding: An observational study[J]. Hepatology, 2019, 69(1): 282-293. DOI: 10.1002/hep.30182.
[40]	LIU FQ, YUE ZD, ZHAO HW, et al. Analysis of technique and perioperative safety of transjugular intrahepatic porto-systemic shunt[J]. Chin J Dig, 2013, 33(5): 331-335. DOI: 10.3760/cma.j.issn.0254-1432.2013.05.011. 刘福全, 岳振东, 赵洪伟, 等. 经颈静脉肝内门体静脉分流术操作技术与围手术期安全性分析[J]. 中华消化杂志, 2013, 33(5): 331-335. DOI: 10.3760/cma.j.issn.0254-1432.2013.05.011.
[41]	WANG L, XIAO Z, YUE Z, et al. Efficacy of covered and bare stent in TIPS for cirrhotic portal hypertension: A single-center randomized trial[J]. Sci Rep, 2016, 6: 21011. DOI: 10.1038/srep21011.
[42]	LV Y, QI X, HE C, et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: A randomised controlled trial[J]. Gut, 2018, 67(12): 2156-2168. DOI: 10.1136/gutjnl-2017-314634.
[43]	JOGO A, NISHIDA N, YAMAMOTO A, et al. Selective Balloon-occluded retrograde transvenous obliteration for gastric varices[J]. Intern Med, 2019, 58(16): 2291-2297. DOI: 10.2169/internalmedicine.2356-18.
[44]	MERCADO MA. Surgical treatment for portal hypertension[J]. Br J Surg, 2015, 102(7): 717-718. DOI: 10.1002/bjs.9849.
[45]	YANG LY. Attention to the surgical treatment of portal hypertension in China[J]. Chin J Dig Surg, 2018, 17(10): 971-975. DOI: 10.3760/cma.j.issn.1673-9752.2018.10.001. 杨连粤. 重视我国门静脉高压症外科治疗的问题[J]. 中华消化外科杂志, 2018, 17(10): 971-975. DOI: 10.3760/cma.j.issn.1673-9752.2018.10.001.
[46]	QI ZR, ZHAO X, WANG SZ, et al. Postoperative complications and survival analysis of 1 118 cases of open splenectomy and azygoportal disconnection in the treatment of portal hypertension[J]. Chin J Surg, 2018, 56(6): 436-441. DOI: 10.3760/cma.j.issn.0529-5815.2018.06.010. 齐瑞兆, 赵新, 王胜智, 等. 1118例开腹脾切除断流术治疗门静脉高压症术后并发症及生存分析[J]. 中华外科杂志, 2018, 56(6): 436-441. DOI: 10.3760/cma.j.issn.0529-5815.2018.06.010.
[47]	HUO F, CHEN JX, ZHENG YJ, et al. Effects, status and problems of liver transplantation in the treatment of portal hypertension[J]. Chin J Dig Surg, 2018, 17(10): 976-980. DOI: 10.3760/cma.j.issn.1673-9752.2018.10.002. 霍枫, 陈建雄, 郑于剑, 等. 肝移植治疗门静脉高压症的作用与地位及需要注意的问题[J]. 中华消化外科杂志, 2018, 17(10): 976-980. DOI: 10.3760/cma.j.issn.1673-9752.2018.10.002.
[48]	Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis(2020, Shanghai)[J]. J Clin Hepatol, 2020, 36(12): 2667-2674. DOI: 10.3969/j.issn.1001-5256.2020.12.007. 中华医学会消化病学分会肝胆疾病学组. 肝硬化门静脉血栓管理专家共识(2020年, 上海)[J]. 临床肝胆病杂志, 2020, 36(12): 2667-2674. DOI: 10.3969/j.issn.1001-5256.2020.12.007.
[49]	MANTAKA A, AUGOUSTAKI A, KOUROUMALIS EA, et al. Portal vein thrombosis in cirrhosis: Diagnosis, natural history, and therapeutic challenges[J]. Ann Gastroenterol, 2018, 31(3): 315-329. DOI: 10.20524/aog.2018.0245.
[50]	STINE JG, NORTHUP PG. Management of Non-tumoral Portal Vein Thrombosis in Patients with Cirrhosis[J]. Dig Dis Sci, 2019, 64(3): 619-626. DOI: 10.1007/s10620-018-5427-3.
[51]	QI XL. Full-course management of portal hypertension: Simplicity is the ultimate sophistication[J]. Chin J Hepatol, 2020, 28(9): 721-723. DOI: 10.3760/cma.j.cn501113-20200831-00487. 祁小龙. 门静脉高压全病程管理: 至繁归于至简[J]. 中华肝脏病杂志, 2020, 28(9): 721-723. DOI: 10.3760/cma.j.cn501113-20200831-00487.
[52]	MANDORFER M, HERNÁNDEZ-GEA V, GARCÍA-PAGÁN JC, et al. Noninvasive diagnostics for portal hypertension: A comprehensive review[J]. Semin Liver Dis, 2020, 40(3): 240-255. DOI: 10.1055/s-0040-1708806.
[53]	SINGH S, MUIR AJ, DIETERICH DT, et al. American Gastroenterological Association Institute technical review on the role of elastography in chronic liver diseases[J]. Gastroenterology, 2017, 152(6): 1544-1577. DOI: 10.1053/j.gastro.2017.03.016.
[54]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460. DOI: 10.1016/j.jhep.2018.03.024.
[55]	QI X, AN W, LIU F, et al. Virtual hepatic venous pressure gradient with CT angiography (CHESS 1601): A prospective multicenter study for the noninvasive diagnosis of portal hypertension[J]. Radiology, 2019, 290(2): 370-377. DOI: 10.1148/radiol.2018180425.
[56]	LIU F, NING Z, LIU Y, et al. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): A prospective multicenter study[J]. EBioMedicine, 2018, 36: 151-158. DOI: 10.1016/j.ebiom.2018.09.023.
[57]	SANDAHL TD, MCGRAIL R, MØLLER HJ, et al. The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis[J]. Aliment Pharmacol Ther, 2016, 43(11): 1222-1231. DOI: 10.1111/apt.13618.
[58]	PALANIYAPPAN N, COX E, BRADLEY C, et al. Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging[J]. J Hepatol, 2016, 65(6): 1131-1139. DOI: 10.1016/j.jhep.2016.07.021.
[59]	CHOUHAN MD, MOOKERJEE RP, BAINBRIDGE A, et al. Caval subtraction 2D phase-contrast MRI to measure total liver and hepatic arterial blood flow: Proof-of-principle, correlation with portal hypertension severity and validation in patients with chronic liver disease[J]. Invest Radiol, 2017, 52(3): 170-176. DOI: 10.1097/RLI.0000000000000328.
[60]	DANG XW, FU KK, LI LH. Construction of a multidisciplinary cooperative mode for portal hypertension[J]. J Clin Surg, 2018, 26(5): 327-328. DOI: 10.3969/j.issn.1005-6483.2018.05.002. 党晓卫, 付坤坤, 李路豪. 门静脉高压症多学科协作模式构建[J]. 临床外科杂志, 2018, 26(5): 327-328. DOI: 10.3969/j.issn.1005-6483.2018.05.002.